Weekly Sepsis Research Analysis
This week’s sepsis literature is dominated by practice-changing clinical trials and pragmatic stewardship studies. Large adaptive randomized trials and multicentre RCTs provide strong evidence favoring safer beta‑lactam choices (cefazolin; benzylpenicillin for PSSA) without compromising mortality, while a national neonatal RCT supports individualized, shorter antibiotic courses for culture‑negative early‑onset sepsis. Complementary observational and mechanistic studies reinforce rapid risk strat
Summary
This week’s sepsis literature is dominated by practice-changing clinical trials and pragmatic stewardship studies. Large adaptive randomized trials and multicentre RCTs provide strong evidence favoring safer beta‑lactam choices (cefazolin; benzylpenicillin for PSSA) without compromising mortality, while a national neonatal RCT supports individualized, shorter antibiotic courses for culture‑negative early‑onset sepsis. Complementary observational and mechanistic studies reinforce rapid risk stratification (ferritin, RAR) and precision strategies (PK/PD dosing, WGS surveillance) to guide implementation.
Selected Articles
1. Cefazolin for Methicillin-Susceptible
In an international Bayesian adaptive, open‑label randomized comparison, cefazolin achieved noninferior 90‑day mortality versus antistaphylococcal penicillins and significantly reduced acute kidney injury. Probabilities strongly favored noninferiority for mortality and superiority for kidney safety, supporting cefazolin as a safer definitive beta‑lactam option for methicillin‑susceptible infections.
Impact: Provides high‑quality, randomized evidence resolving a longstanding clinical question about optimal definitive therapy for MSSA-like infections and demonstrates a clear safety advantage (less AKI) without compromising survival.
Clinical Implications: When methicillin‑susceptible Staphylococcus aureus (or similar MSS pathogens) is confirmed, clinicians should consider cefazolin over antistaphylococcal penicillins to minimize nephrotoxicity while maintaining outcomes; implement workflows for rapid susceptibility confirmation to enable timely de‑escalation.
Key Findings
- 90‑day mortality: 15.0% (cefazolin) vs 17.0% (anti‑staphylococcal penicillins); adjusted OR 0.81 (95% CrI 0.59–1.12); probability of noninferiority 99.2%.
- Acute kidney injury: 13.9% (cefazolin) vs 19.6% (antistaphylococcal penicillins); adjusted OR 0.67 (95% CrI 0.50–0.89); high probability of superiority for kidney safety.
2. Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.
In adults with penicillin‑susceptible Staphylococcus aureus bacteraemia, benzylpenicillin had a high posterior probability of noninferiority for 90‑day mortality versus flucloxacillin/cloxacillin and was associated with substantially less acute kidney injury. Recruitment was stopped early because of excess AKI in the anti‑staphylococcal penicillin arm, indicating a favorable benefit–harm profile for benzylpenicillin in confirmed PSSA.
Impact: Pragmatic international RCT evidence supports using benzylpenicillin as a safer definitive agent for confirmed PSSA bacteraemia—an actionable change that reduces nephrotoxicity while preserving survival.
Clinical Implications: Adopt benzylpenicillin for confirmed PSSA bacteraemia where available and supported by susceptibility testing; ensure laboratory workflows enable timely differentiation of PSSA to permit de‑escalation from broader regimens.
Key Findings
- 90‑day mortality: 14% (benzylpenicillin) vs 22% (flucloxacillin/cloxacillin); adjusted OR 0.67 (95% CrI 0.35–1.28).
- AKI: 11% (benzylpenicillin) vs 22% (antistaphylococcal penicillins); adjusted OR 0.50; recruitment stopped early due to AKI imbalance.
3. Individualised duration of antibiotic treatment in culture-negative early-onset sepsis in late-preterm and term-born neonates in Denmark (DURATION): a multicentre, open-label, randomised, controlled, non-inferiority trial.
Nationwide multicentre RCT in Denmark showed that an individualized, clinically guided discontinuation rule (stop at 24 h if no signs and CRP declining to ≤30 mg/L) was non‑inferior for infection‑related readmission and reduced median antibiotic duration to ~3 days compared with standard 5–7 days in culture‑negative early‑onset neonates, supporting stewardship in a high‑use population.
Impact: High‑quality neonatal RCT demonstrating safe antibiotic‑duration reduction in probable EOS—directly applicable to antimicrobial stewardship and neonatal care pathways.
Clinical Implications: Implement individualized stop rules using serial clinical assessment and CRP kinetics (e.g., stop at 24 h if no signs and CRP ≤30 mg/L) to safely reduce antibiotic exposure in culture‑negative probable EOS, with monitoring for readmission and robust follow‑up.
Key Findings
- Randomized 493 neonates (246 individualized vs 247 standard nationwide).
- Readmission due to bacterial infection: 1% individualized vs <1% standard; non‑inferiority met. Median antibiotic duration reduced to ~3 days vs 5–7 days standard.